Explore the rise of China as a global biopharma epicenter, driven by multi-billion dollar licensing deals with Merck, AstraZeneca and AbbVie in oncology and obesity. Over the past 16 months, Chinese-domiciled biotechs have featured in roughly 6 of every 26 major pharma licensing and acquisition deals, accounting for nearly one-third of total headline value. Roughly half of those deals involve firms of U.S. origin, mostly involving M&A. Just under 30% involves licensing deals with Chinese-headquartered firms while the remainder involves mixed deals involving European firms. In December 2024, Merck licensed Jiangsu Province, China–headquartered Hansoh Pharma’s oral obesity candidate HS-10535 in…
Over the past 16 months, Chinese-domiciled biotechs have featured in roughly 6 of every 26 major pharma licensing and acquisition deals, accounting for nearly one-third of total headline value. Roughly half of those deals involve firms of U.S. origin, mostly involving M&A. Just under 30% involves licensing deals with Chinese-headquartered firms while the remainder involves…
The post Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion appeared first on Drug Discovery and Development.
US Pharma Marketing